Heart rhythm safety study of olpasiran completed in healthy adults
NCT ID NCT06411860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checked whether a single dose of olpasiran (AMG 890) affects the heart's electrical activity in 32 healthy adults aged 18 to 60. Participants received olpasiran, a placebo, and a positive control in random order. The main goal was to measure changes in the QT interval, a heart rhythm marker. No treatment benefit was expected or provided.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASIC SCIENCE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit Limited - Leeds
Leeds, LS11 9EH, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain scans reveal LSD's grip on serotonin receptors
- Radioactive tag reveals Drug's exit route in tiny trial
- Mint lozenge and water additive tested for microbiome impact in 595-Person study
- One hard bike ride could change your balance and brain – study reveals
- Brain study seeks to unlock secrets of hand coordination
- Brain zapping study reveals secrets of body awareness and skill learning